Tg Therapeutics, Inc.
tgtherapeutics.comTG Therapeutics is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for Ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of Multiple Sclerosis (RMS).
Is this your company?
If you're responsible for hiring at this company, make sure your company and job information are always up to date to attract top talent from the North Carolina Biotechnology Center network.
Something looks off?
Open jobs at Tg Therapeutics, Inc.
On-site & Remote
Job function
Seniority
Salary